In this issue:
IMvigor130: final OS results part 1
IMvigor130: final OS results part 2
Radical cystectomy vs. bladder-preserving therapy for MIBC
Gemcitabine + docetaxel for non-invasive, high-grade UTUC
BCG in immunomodulated patients with NMIBC
Intravesical gemcitabine + docetaxel for intermediate-risk NMIBC
BCG for NMIBC in patients >70 years
IMvigor010: atezolizumab in ctDNA-positive MIUC
Javelin Bladder 100: efficacy of avelumab by time factors
BCG dose reductions for NMIBC
Please login below to download this issue (PDF)